Kodiak Sciences Raises $69 Million As It Heads Toward Retinal Drug Approval Applications
Management expects cash to support operations into 2027, with December results ahead for its treatment of inflammation-related retinal swelling.
Kodiak Sciences, which develops medicines for retinal diseases, raised $69 million from stock sales after quarter-end as it works toward drug approval applications. In its earnings release attached to Thursday's SEC filing, management said it expects current cash to support operations into 2027.
New Cash, More Shares
Kodiak held $88.7 million in cash and cash equivalents at the end of September. The subsequent $69 million in net proceeds came through a program that sells common shares into the market.
The third-quarter loss grew to $66.2 million from $61.5 million a year earlier, including non-cash stock compensation of $12.8 million, compared with $14.0 million. Yet the loss per share narrowed to $1.05 from $1.16: average shares outstanding increased to 62,960,644 from 52,859,308.
Kodiak's cash outlook sits alongside a financial warning. The company said its financial condition raises substantial doubt about its ability to continue operating as a going concern.
Trials And Manufacturing Cost More
Research and development spending reached $58.3 million in the third quarter, versus $50.5 million a year earlier. Kodiak attributed the increase mainly to trial work on its inflammation-related retinal swelling and diabetic macular edema programs, plus manufacturing for late-stage development.
Research costs included $6.7 million in non-cash stock compensation, down from $7.2 million. Administrative spending fell to $8.8 million from $11.9 million, with stock compensation accounting for $6.1 million versus $6.9 million.
Kodiak attributed the rest of the administrative decrease primarily to a one-time, non-cash gain from ending a Palo Alto building lease. In exchange, it received an option to lease another building on the same campus with lease incentives.
December's Retinal Swelling Readout
Kodiak has no approved products and retains global rights to its drug candidates. Its technology links antibodies with a biopolymer to extend their activity in the eye; its late-stage portfolio includes Zenkuda, tabirafusp-ted, also called KSI-501, and KSI-101.
Chief Executive Officer Victor Perlroth said, "we expect to announce the first Phase 3 KSI-101 results in December." Enrollment is complete for the initial 300-patient group testing the treatment for retinal swelling caused by inflammation.
Kodiak expects to finish enrolling a second pivotal group of 600 patients across its PEAK and PINNACLE late-stage trials in the fourth quarter. Results are anticipated in the second quarter of 2027, when the company also plans a KSI-101 approval application if the results succeed.
Zenkuda and tabirafusp-ted met their goals in a pivotal wet age-related macular degeneration trial, Kodiak announced on September 28. Under retreatment rules requiring retinal dryness, 54% of Zenkuda patients received treatment every six months. Tabirafusp-ted is also being tested in the enrolling ALTO late-stage trial for diabetic macular edema.
Kodiak plans to submit Zenkuda's approval application by year-end, drawing on five successful late-stage studies covering wet age-related macular degeneration, diabetic retinopathy and retinal vein occlusion.
Sources
- 8-K Filing — Kodiak Sciences Inc. (KOD) — SEC EDGAR
- Exhibit kod-ex99_1.htm — Kodiak Sciences Inc. 8-K exhibit — SEC EDGAR
- 8-K filed 2026-09-28 — Kodiak Sciences Inc. (earlier disclosure) — SEC EDGAR